65,437 trials
Eosinophilic Esophagitis (EoE)
Primary: Percent of Participants Who Were Histologic Responders — 2.6; 38.8 percent of participants — p=<0.0001
Obesity
Primary: %Excess Weight Loss — 20.2; 12.7 percent excess weight loss — p=0.2922
Multiple Sclerosis
Primary: Difference in Ashworth Spasticity Scale Score Between Baseline and 12 Weeks — -1.55; -1.00 units on a scale
Autism Spectrum Disorder
Primary: Patient Satisfaction — 95.08; 95.96; 96.8; 92.11 percentage of participants
Patients Undergoing Any Kind of Surgery
Primary: Number of Different Substitution Solutions Administered — 7827; 1055; 221 participants
Hepatitis B, Chronic
Primary: Percentage of Participants With Suppression of HBV DNA to < 2,000 IU/ml at the End of the Study — 38.8 Percentage of participants
Total Knee Arthroplasty
Primary: Mean Triathlon CR Active Range of Motion (ROM) — 112.96 degree
Osteoarthritis, Knee
Primary: Number of Participants With Viable Specimens for Genetic Analysis — 14 participants
Lymphoma · B-cell Non-Hodgkin's Lymphoma
Primary: Improve the Overall Response Rate — 4; 2; 7; 4 participants
Hepatocellular Carcinoma
Primary: Overall Survival - Overall Survival — 33; 39.4 Weeks
Epilepsy · Partial-onset Seizures
Primary: The Total Number of Subjects Experiencing at Least One Adverse Event During the Study — 4 participants
Prostatic Neoplasms
Primary: Progression Free Survival (PFS) Based on Independent Central Review (ICR) Assessment — 15.7; 5.8 months — p=<0.0001
Chronic Renal Insufficiency · Type 2 Diabetes Mellitus
Primary: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞) of Omarigliptin — 4703.16; 4983.58; 5785.21; 4312.17 nM*hr
Major Depressive Disorder
Primary: Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score. — -6.62; -6.46…
Parkinson Disease
Primary: Change From Baseline (BL) in Total Awake Time Spent "Off" at Week 4 of Maintenance Period — -1.91; -2.04; -2.92; -2.34 Hours — p=0.814